ACE and hypertensive disorder: Spirapril (Figure 10), a spirocyclic inhibitor of the angiotensin-converting enzyme (ACE) had been originated and developed by the Schering-Plough Corporation (now Merck & Co.)and was approved in 1995 for the treatment of hypertension.